SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Reports Pimicotinib Sustains Tumor Response Over Two Years in Phase 3 TGCT Trial

Valid market news retained in the public archive without immediate LiveCast distribution.

MERCK

Related stories